AXL and ovarian cancer: Because AXL downregulation has been shown to be an attractive therapeutic target for ovarian cancer [156,168,169,170,171], Kanlikilicer et al. created and tested a serum-stable DNA version of GL21.T, called AXL-DNA-APTAMER, containing both 2′-fluoropyrimidine nucleosides and thiophosphates [172], and tested its effects on ovarian cancer.